Likewise, our in-silico interactome proposed that POM121, beyond the transcription factors described, binds oncogenic drivers of CRC (e.g., APC) and clinical immune checkpoints (e.g., CTLA4). This evidence concerns the gene POM121 and colorectal carcinoma.